The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials.

Abstract

Astemizole is a new H1 histamine-receptor antagonist that has a long elimination half-life and high H1-receptor affinity. This double-blind study evaluated the safety and efficacy of astemizole in the treatment of chronic idiopathic urticaria (more than or equal to 3 months). Seventeen male and 34 female adult patients with chronic idiopathic urticaria… (More)

Topics

Cite this paper

@article{Fox1986TheTO, title={The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials.}, author={R. W. Fox and Rachael Lockey and Samuel C. Bukantz and D E Serbousek}, journal={The Journal of allergy and clinical immunology}, year={1986}, volume={78 6}, pages={1159-66} }